Bivalirudin
Zaporedje:D-Phe-Pro-Arg-Pro-Gly-Gly-Gly-Gly-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-OH
vzdevek:126:PN:WO2004076484PAGE:31 zahtevane beljakovine;Angiomaks;BG 8967;Bivalirudin;Hirulog; Hirulog 1
Cas Št.: 128270-60-0
Molekularna formula: C98H138N24O33
Molekularna teža: 2180.29
Čistost (HPLC): 98.0%min.
Videz: Bel prah
Ena nečistoča (HPLC): 1.0%maks
Aminokislinska sestava: ±10 % teoretičnega
Vsebnost peptidov (N%): >80.0%
Vsebnost vode (Karl Fischer): <8.0%
Vsebnost trifluoroacetata(HPIC): >12.0%
GOSPA (ESI): Dosledno
Masno ravnotežje: 95.0~105,0 %
Ocena : Farmacevtski razred
Shranjevanje: Zaprto, spodaj 2 ~ 8℃ ohranjanje
Uporaba : Ta izdelek se v glavnem uporablja za preprečevanje vaskularne intervencijske terapije pri zdravljenju nestabilne angine, ishemičnih zapletov pred in po. Zavira trombin v obtoku in trombin, vezan na strdek., hkrati pa tudi zavira aktivacijo in agregacijo trombocitov, posredovano s trombinom.
Bivalirudin (Angiomax or Angiox, manufactured by The Medicines Company) is a specific and reversible direct thrombin inhibitor (DTI).
Bivalirudin is a DTI that overcomes many limitations seen with indirect thrombin inhibitors, such as heparin. Bivalirudin is a short, synthetic peptide that is potent, highly specific, and a reversible inhibitor of thrombin. It inhibits both circulating and clot-bound thrombin, hkrati pa tudi zavira aktivacijo in agregacijo trombocitov, posredovano s trombinom. Bivalirudin has a quick onset of action and a short half-life. It does not bind to plasma proteins (other than thrombin) or to red blood cells. Therefore it has a predictable antithrombotic response. There is no risk for Heparin Induced Thrombocytopenia/Heparin Induced Thrombosis-Thrombocytopenia Syndrome (HIT/HITTS). It does not require a binding cofactor such as antithrombin and does not activate platelets. These characteristics make bivalirudin an ideal alternative to heparin.
Bivalirudin clinical studies demonstrated consistent positive outcomes in patients with stable angina, unstable angina (UA), non-ST segment elevation myocardial infarction (NSTEMI), and ST-segment elevation myocardial infarction (STEMI) undergoing PCI in 7 major randomized trials
Bivalirudin is indicated for use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA).
Bivalirudin with provisional use of glycoprotein IIb/IIIa inhibitor (GPI) is indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI).
Bivalirudin is indicated for patients with, or at risk of HIT/HITTS undergoing PCI.
Bivalirudin is intended for use with aspirin and has been studied only in patients receiving concomitant aspirin.
